Tech Center 1600 • Art Units: 1658
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18252069 | METHOD OF SENSITIZING CANCERS TO IMMUNOTHERAPY USING IMMUNOMODULATORY AGENTS | Non-Final OA | The Regents of the University of California |
| 18030433 | CHIMERIC CONJUGATES FOR DEGRADATION OF VIRAL AND HOST PROTEINS AND METHODS OF USE | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18550862 | BECLIN 1-TARGETED STAPLED PEPTIDE AND PHARMACEUTICAL COMPOSITION | Non-Final OA | FUDAN UNIVERSITY |
| 18278508 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING DISEASE CAUSED BY PROTEIN NITRATION COMPRISING PEPTIDE WITH TERMINAL TYROSINE AS EFFECTIVE COMPONENT | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY |
| 18139254 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4B7 INTEGRIN ANTAGONISTS | Non-Final OA | Protagonist Therapeutics, Inc. |
| 18273868 | Treatment Of Integrin-Related Disorders With Stapled Peptides | Non-Final OA | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
| 18455196 | Wound Healing Promoting Protein | Non-Final OA | Eberhard Karls Universität Tuebingen Medizinische Fakultät |
| 18222784 | COMBINED USE OF NANOBODY, CYCLODEXTRIN AND QUERCETIN FOR PROTECTION FROM ENVELOPED VIRUSES | Non-Final OA | VIRON, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy